

## I. Editorial Features

### IN THIS ISSUE....

#### EDITORIAL COMMENTS

##### **EUNEFRON, the European Network for the Study of Orphan Nephropathies**

O. Devuyst, I. Meij, X. Jeunemaitre, P. Ronco, C. Antignac, E. I. Christensen, N. V. Knoers, E. N. Levchenko, P. M. Deen, D. Müller, C. A. Wagner, L. Rampoldi, W. G. van't Hoff and On behalf of the EUNEFRON consortium

2011

##### **This extraordinary extramedullary haematopoiesis**

M. S. Goligorsky  
(See related article by I. Stroo *et al.* Haematopoietic stem cell migration to the ischemic damaged kidney is not altered by manipulating the SDF-1/CXCR4-axis. *Nephrol Dial Transplant* 2009; 24: 2082–2088.)

2016

##### **The plasticity of progenitor cells—why is it of interest to the nephrologists?**

F. H. Bahlmann and D. Fliser

2018

##### **Inhibition of protein kinase C in diabetic nephropathy—where do we stand?**

J. Menne, M. Meier, J.-K. Park and H. Haller

2021

##### **A critical look at acute decompensated heart failure from a nephrologist's perspective**

C. T. Chan

2024

##### **Transplantation in type 1 diabetes**

C. Morath and M. Zeier

2026

#### EDITORIAL REVIEW

##### **Nephrocalcinosis: new insights into mechanisms and consequences**

B. A. Vervaet, A. Verhulst, P. C. D'Haese and M. E. De Broe

2030

#### TRANSLATIONAL NEPHROLOGY

##### **The Jupiter trial—new territory for statins?**

D. C. Wheeler

2036

## II. Scientific Papers

### ORIGINAL ARTICLES

#### EXPERIMENTAL NEPHROLOGY

##### **CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney**

J. Nyström, K. Hultén, S. Ek, J. Sjölund, H. Axelson, K. Jirstrom, M. A. Saleem, K. Nilsson and M. E. Johansson

2038

##### **Glomerular filtration is normal in the absence of both agrin and perlecan–heparan sulfate from the glomerular basement membrane**

S. Goldberg, S. J. Harvey, J. Cunningham, K. Tryggvason and J. H. Miner

2044

##### **Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells**

G. Muteliefu, A. Enomoto, P. Jiang, M. Takahashi and T. Niwa

2051

##### **Regulation of amino acid transporters in the rat remnant kidney**

J. S. Amaral, M. J. Pinho and P. Soares-da-Silva

2058

##### **Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy**

J. Xiao, J. C. K. Leung, L. Y. Y. Chan, H. Guo and K. N. Lai

2067

##### **Efficacy of the combination of N-acetylcysteine and desferrioxamine in the prevention and treatment of gentamicin-induced acute renal failure in male Wistar rats**

F. Petronilho, L. Constantino, B. de Souza, A. Reinke, M. R. Martins, C. M. Fraga, C. Ritter and F. Dal-Pizzol

2077

##### **Haematopoietic stem cell migration to the ischemic damaged kidney is not altered by manipulating the SDF-1/CXCR4-axis**

I. Stroo, G. Stokman, G. J. D. Teske, S. Florquin and J. C. Leemans

(See related article by M. S. Goligorsky. This extraordinary extramedullary haematopoiesis. *Nephrol Dial Transplant* 2009; 24: 2016–2017.)

2082

#### CLINICAL NEPHROLOGY

##### **Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress**

H. Fujii, F. Nishijima, S. Goto, M. Sugano, H. Yamato, R. Kitazawa, S. Kitazawa and M. Fukagawa

2089

##### **Association of kidney function and uncarboxylated matrix Gla protein: Data from the Heart and Soul Study**

B. D. Parker, J. H. Ix, E. C. M. Cranenburg, C. Vermeer, M. A. Whooley and L. J. Schurgers

2095

##### **Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy**

R. Schiffmann, D. G. Warnock, M. Banikazemi, J. Bultas, G. E. Linthorst, S. Packman, S. A. Sorensen, W. R. Wilcox and R. J. Desnick

2102

##### **Prevalence of microalbuminuria and associated electrocardiographic abnormalities in an Indo-Asian population**

T. H. Jafar, Z. Qadri and S. Hashmi

2111

##### **Community-based study on CKD subjects and the associated risk factors**

N. Chen, W. Wang, Y. Huang, P. Shen, D. Pei, H. Yu, H. Shi, Q. Zhang, J. Xu, Y. Lv and Q. Fan

2117

##### **Glomerular filtration rate and serum phosphate: an inverse relationship diluted by age**

M. Cirillo, G. Botta, D. Chiricone and N. G. De Santo

2123

##### **Low-density lipoprotein clearance in patients with chronic renal failure**

H. Kastarinen, S. Hörrkö, H. Kauma, A. Karjalainen, M. J. Savolainen and Y. A. Kesäniemi

2131

##### **Reported cancer screening practices of nephrologists: results from a national survey**

G. Wong, A. C. Webster, J. R. Chapman and J. C. Craig

2136

##### **Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study**

S. Lionaki, K. Siamopoulos, I. Theodorou, E. Papadimitrakí, G. Bertias, D. Boumpas and J. Boletis

2144

##### **Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis**

B. Wilde, P. van Paassen, J. Damoiseaux, P. Heerings-Rewinkel, H. van Rie, O. Witzke and J. W. Cohen Tervaert

2151

##### **Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study**

J. N. Boletis, S. Marinaki, C. Skalioti, S. S. Lionaki, A. Iniotaki and P. P. Sfakakis

2157

##### **Urinary proteome pattern in children with renal Fanconi syndrome**

J. Drube, E. Schiffer, H. Mischak, M. J. Kemper, T. Neuhaus, L. Pape, R. Lichtinghagen and J. H. H. Ehrich

2161

**Incidental renal artery calcifications: a study of 350 consecutive abdominal computed tomography scans**  
L. Tolkin, M. Bursztyn, I. Z. Ben-Dov, N. Simanovsky and N. Hiller

2170

**Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement**  
F. Aregger, P. Wenaweser, G. J. Hellige, A. Kadner, T. Carrel, S. Windecker and F. J. Frey

2175

**The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit**  
R. Faulhaber-Walter, C. Hafer, N. Jahr, J. Vahlbruch, L. Hoy, H. Haller, D. Fliser and J. T. Kielstein

2179

**Long-term prognosis after acute kidney injury requiring renal replacement therapy**  
P.-A. Triverio, P.-Y. Martin, J. Romand, J. Pugin, T. Perneger and P. Saudan

2186

#### DIALYSIS

**Characteristic differences in cephalic arch geometry for diabetic and non-diabetic ESRD patients**  
M. S. Hammes, M. E. Boghosian, K. W. Cassel, B. Funaki and F. L. Coe

2190

**Impact of switch of vascular access type on key clinical and laboratory parameters in chronic haemodialysis patients**  
G. Wystrychowski, T. M. Kitzler, S. Thijssen, L. Usvyat, P. Kotanko and N. W. Levin

2194

**Functional and structural response of arterialized femoral veins in a rodent AV fistula model**  
S. Langer, C. Heiss, N. Paulus, N. Bektas, G. Mommertz, Z. Rowinska, R. Westenfeld, M. J. Jacobs, M. Fries, T. A. Koepfel and European Vascular Center Aachen-Maastricht

2201

**Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients**  
M. Cozzolino, M. L. Biondi, A. Galassi, O. Turri, D. Brancaccio and M. Gallieni

2207

**The plasma retinol levels as pro-oxidant/oxidant agents in haemodialysis patients**  
M. Roehrs, J. Valentini, R. Bulcão, J. C. Moreira, H. Biesalski, R. P. Limberger, T. Grune and S. C. Garcia

2212

**A diffusion-adjusted regional blood flow model to predict solute kinetics during haemodialysis**  
D. Schneditz, D. Platzer and J. T. Daugirdas

2218

**Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis**  
S. Eloit, W. van Biesen, A. Dhondt, R. de Smet, B. Marescau, P. P. De Deyn, P. Verdonck and R. Vanholder

2225

**Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy**  
S. David, P. Kümpers, G. M. Eisenbach, H. Haller and J. T. Kielstein

2232

**False low parathyroid hormone values secondary to sample contamination with the tissue plasminogen activator**  
B. Schiller, A. Wong, M. Blair and J. Moran

2240

**Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation**  
J. Kozik-Jaromin, V. Nier, U. Heemann, B. Kreyman and J. Böhrer

2244

**The value of QuantiFERON® TB-Gold in the diagnosis of tuberculosis among dialysis patients**  
T. Inoue, T. Nakamura, A. Katsuma, S. Masumoto, E. Minami, D. Katagiri, T. Hoshino, M. Shibata, M. Tada and F. Hinoshita

2252

#### TRANSPLANTATION

**The cost-effectiveness of induction immunosuppression in kidney transplantation**  
R. L. Morton, K. Howard, A. C. Webster, G. Wong and J. C. Craig

2258

**The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy**  
J. M. Grinyó, H. Ekberg, R. D. Mamelok, F. Oppenheimer, J. Sánchez-Plumed, M. A. Gentil, D. Hernandez, D. R. Kuypers and M. Brunet

2269

**Renal biopsy in liver transplant recipients**  
A. O'Riordan, N. Dutt, H. Cairns, M. Rela, J. G. O'Grady, N. Heaton and B. M. Hendry

2276

#### EXCEPTIONAL CASE

**Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis—a single case**  
J. T. Kielstein, J. Lorenzen, V. Kaever, H. Burhenne, M. Broll, C. Hafer and O. Burkhardt

2283

### III. Varia

#### LETTERS

**Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?**  
W. van Biesen, S. Van Laecke and R. Vanholder

2286

**Metformin in renal failure—weigh the evidence**  
M. K. Mani

2287

#### LETTERS AND REPLIES

**Anaemia ERBP Position statement**  
I. C. Macdougall

2288

**Reply**  
F. Locatelli, on behalf of Anaemia ERBP Group

2288

**Post-conditioning to reduce renal ischaemia/reperfusion injury**  
I. Szwarz, G. Mourad and A. Argiles

2288

**Reply**  
L. Gesualdo and G. Serviddio

2289

**Outcomes of critically ill patients with acute kidney injury and end-stage renal disease requiring renal replacement therapy: a case-control study**  
S. A. Hussain and E. P. Cohen

2290

**Reply**  
E. Rocha, M. Soares and E. Maccariello

2290

**First use of femoral artery catheterization for haemodialysis**  
S. Shaldon

2291

**Reply**  
E. S. Chemla and A. Frampton

2291

**Limitations of non-corrected and albumin-corrected total calcium concentrations in CKD patients**  
M. Froissart, P. Houillier, on behalf of the NephroTest Study Group

2291

**Reply**  
L. Labriola, P. Wallemacq and M. Jadoul

2292

**Which laboratory parameters are characteristic for nephrogenic systemic fibrosis?**

I. Boehm

2293

**Reply**

R. Agarwal, S. M. Brunelli and C. A. Umscheid

2293

**Measuring lock solution spillage *in-vivo* versus *in-vitro***

H.-D. Polaschegg

2294

**Reply**

I. Markota

2295

**Letter to the editor regarding 'Acute phase reaction to gadolinium-DTPA in dialysis patients'**

S. Swaminathan and S. V. Shah

2295

**Reply**

H. Steen, V. Schwenger, E. Ritz and M. Zeier

2296

**ANNOUNCEMENTS**

2297